Bank of America’s ImmunityBio IBRX Stock Holding History

Bank of America’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$52.8K	–	8498
2025 Q2	$52.8K	Buy	+20,000	New	+$53.8K	﹤0.01%	6792
2025 Q1	–	Sell	-190,000	Closed	-$486K	–	8407
2024 Q4	$486K	Buy	+190,000	New	+$792K	﹤0.01%	5555
2024 Q3	–	Sell	-350,000	Closed	-$2.21M	–	8283
2024 Q2	$2.21M	Buy	350,000 +85,000	+32%	+$560K	﹤0.01%	4361
2024 Q1	$1.42M	Buy	+265,000	New	+$1.2M	﹤0.01%	4690
2023 Q3	–	Sell	-14,600	Closed	-$40.6K	–	7846
2023 Q2	$40.6K	Buy	+14,600	New	+$41.3K	﹤0.01%	6526
2023 Q1	–	Sell	-9,000	Closed	-$45.6K	–	8007
2022 Q4	$45.6K	Buy	+9,000	New	+$49.4K	﹤0.01%	6502

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Bank of America's IBRX Position: Q1 2026 in Review

Bank of America increased its ImmunityBio (IBRX) stake by 2.7% in Q1 2026, buying an estimated $447K and bringing the position to 2,447,843 shares worth $18.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2444.

Bank of America first reported a position in IBRX in Q3 2015 and has held it in 43 quarters since. The position peaked at $23.1M in Q2 2025. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Bank of America held 2,447,843 shares of ImmunityBio worth $18.8M as of Q1 2026.
Bank of America bought 65,340 ImmunityBio shares in Q1 2026, an estimated $447K.
ImmunityBio made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2444 holding.
Bank of America first reported a position in ImmunityBio in Q3 2015 and has held it in 43 quarters since.
Bank of America's ImmunityBio position peaked at $23.1M in Q2 2025.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.